Submitted:
31 December 2024
Posted:
06 January 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Cirrhosis and CYP Isoenzymes
3. Trends in Cirrhosis Diagnosis
4. Paraclinic Key Points in Cirrhosis Diagnosis
5. Conclusions
References
- Kleinbloesem CH, van Harten J, Wilson JP, Danhof M, van Brummelen P, Breimer DD. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther. 1986;40:21–8. [CrossRef] [PubMed]
- Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet. 1995;29:370–91. [CrossRef]
- Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews. 2002;54:1271–94. [CrossRef]
- George J, Liddle C, Murray M, Byth K, Farrell GC. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol. 1995;49:873–81. [CrossRef] [PubMed]
- Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther. 1991;256:1189–94. [CrossRef] [PubMed]
- Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992;51:229–38. [CrossRef]
- Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NP, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol. 1984 Nov 15;33(22):3721–3724. [CrossRef]
- Kleinbloesem CH, Van Harten J, Van Brummelen P, Breimer DD. Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. J Chromatogr. 1984 Jun 8;308:209–216. [CrossRef]
- van Harten J, van Brummelen P, Wilson JH, Lodewijks MT, Breimer DD. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. Eur J Clin Pharmacol. 1988;34:387–94. [CrossRef]
- Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, editors. Oxford Textbook of Clinical Hepatology. 2nd Edition Oxford University Press; 1999.
- Sherlock S, Dooley J, editors. Diseases of the Liver and Biliary System. 11th Edition Blackwell Science; Oxford, UK; Malden, MA: 2002.
- Schiff ER, Sorrell MF, Maddrey EC, editors. Schiff’s Diseases of the Liver. 9th Edition Lippincott, Williams & Wilkins; Philadelphia: 2003.
- Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004;40:860–7. [CrossRef]
- Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599–607. [CrossRef]
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32. [CrossRef] [PubMed]
- Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874–80. [CrossRef] [PubMed]
- Bellentani S, Saccoccio G, Costa G, et al.The Dionysos Study Group Drinking habits as cofactors of risk for alcohol induced liver damage. Gut. 1997;41:845–50.
- Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology. 1995;22:1127–31.
- Conn H, Atterbury C. Cirrhosis. In: Schiff L, Schiff E, editors. Diseases of the Liver. 7th edition Lippencott Company, Philadelphia; Philadelphia: 1993. pp. 875–934.
- Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17. [CrossRef] [PubMed]
- Everson GT. Management of cirrhosis due to chronic hepatitis C. J Hepatol. 2005;42(Suppl1):S65–74. [CrossRef] [PubMed]
- Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857–61. 23.
- Van Thiel DH, Gavaler JS, Schade RR. Liver disease and the hypothalamic pituitary gonadal axis. Semin Liver Dis. 1985;5:35–45. 24. [CrossRef]
- Tangerman A, Meuwese-Arends MT, Jansen JB. Cause and composition of foetor hepaticus. Lancet. 1994;343:483. [CrossRef] [PubMed]
- Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: Diagnosis with sonographic study of the liver surface. Radiology. 1989;172:389–92. [CrossRef]
- Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med. 2002;21:1023–32. [CrossRef] [PubMed]
- Jansen C., Chatterjee D.A., Thomsen K.L.Al-Kassou B., Sawhney R., Jones H., et al., Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality. Aliment Pharmacol Ther. 2019; 50: 568-579. [CrossRef]
- Moreau R., Jalan R., Gines P., Pavesi M., Angeli P., Cordoba J., et al., Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.Gastroenterology. 2013; 144 (37 e1-9): 1426-1437. [CrossRef] [PubMed]
- Moon A.M., Singal A.G., Tapper E.B., Contemporary epidemiology of chronic liver disease and cirrhosis.Clin Gastroenterol Hepatol. 2020; 18: 2650-2666. [CrossRef] [PubMed]
- Trebicka J., Fernandez J., Papp M., Caraceni P., Laleman W., Gambino C., et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020; 73: 842-854. [CrossRef]
- Tapper E.B., Halbert B., Mellinger J., Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol. 2016; 14: 1181-8 e2. [CrossRef] [PubMed]
- Bajaj J.S., Reddy K.R., Tandon P., Wong F., Kamath P.S., Garcia-Tsao G. et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016; 64: 200-208. [CrossRef] [PubMed]
- European Association for the Study of the Liver EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Hepatol. 2018; 69: 406-460.
- Macdonald S., Jepsen P., Alrubaiy L., Watson H., Vilstrup H., Jalan R., Quality of life measures predict mortality in patients with cirrhosis and severe ascites. Aliment Pharmacol Ther. 2019; 49: 321-330. [CrossRef] [PubMed]
- Ballard HS. The hematological complications of alcoholism. Alcohol Health Res World. 1997;21(1):42-52.
- Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol. 1978 Aug;70(2):248-5. [CrossRef]
- Tanaka S, Okamoto Y, Yamazaki M, Mitani N, Nakqjima Y, Fukui H. Significance of hyperglobulinemia in severe chronic liver diseases--with special reference to the correlation between serum globulin/IgG level and ICG clearance. Hepatogastroenterology. 2007 Dec;54(80):2301-5. [PubMed]
- Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med. 2002 Sep;21(9):1023-32; quiz 1033-4. [CrossRef] [PubMed]
- Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614-8.
- Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):22-39.





Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).